X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IncobotulinumtoxinA
Therapeutic Area: Neurology Product Name: Xeomin
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
The approval by European authorities for the use of XEOMIN® for pediatric patients suffering from chronic sialorrhea, was achieved due to the convincing results of the SIPEXI study (Sialorrhea Pediatric Xeomin Investigation).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Levodopa,Carbidopa,Entacapone
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2021
Details:
The novel gel formulation is of the three established Parkinson's active ingredients levodopa, carbidopa and entacapone has a positive effect on the bioavailability of levodopa in the body.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
